logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Pembrolizumab in combination with ipilimumab for advanced non-small cell lung cancer

< Back

Pembrolizumab in combination with ipilimumab for advanced non-small cell lung cancer

Drugs

Cancer and Palliative Care

August 2020


Pembrolizumab in combination with ipilimumab is under development for the treatment of advanced non-small cell lung cancer (NSCLC), which comprises the majority of lung cancers in the UK. Symptoms of lung cancer include a persistent cough, shortness of breath, coughing up blood, aches and pains in the chest or shoulder, loss of appetite, weight loss and fatigue. While current treatments exist for NSCLC, significant unmet medical need remains for more effective treatment options. Combining different technologies targeting complementary pathways might result in additional or complementary antitumor activity.
Pembrolizumab is a humanised monoclonal anti‐programmed cell death‐1 (PD‐1) antibody. Pembrolizumab works by improving the activity of white blood cells in killing cancer cells by blocking PD-L1. Ipilimumab increases the activity of T-cells against cancer cells. If licensed, this combination of pembrolizumab and ipilimumab administered intravenously could offer a treatment for patients with NSCLC whose tumours express high levels of PD-L1.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts